Short Stature and Peptide Therapy: The Evidence
Pediatric Growth Peptides
3.7 → 6.1 cm/yr
Intranasal GHRP-2 increased height velocity from 3.7 to 6.1 cm per year in children with short stature over six months. Growth hormone releasing peptides represent one of several peptide-based approaches to pediatric growth failure.
Pihoker et al., Journal of Endocrinology, 1997
Pihoker et al., Journal of Endocrinology, 1997
View as imageEvery peptide therapy for short stature traces back to a single 191-amino-acid protein: human growth hormone. Recombinant growth hormone (somatropin) is the established treatment for growth hormone deficiency in children, but GH itself is only one node in a peptide signaling cascade that includes growth hormone releasing hormone (GHRH), growth hormone releasing peptides (GHRPs), ghrelin, and insulin-like growth factor 1 (IGF-1). Each of these peptides has been investigated as a therapeutic tool for children who are not growing at expected rates. Pihoker et al. demonstrated in 1997 that intranasal GHRP-2 increased height velocity from 3.7 to 6.1 cm per year in children with short stature, establishing that stimulating the body's own GH production through peptide secretagogues could accelerate growth without daily GH injections.[1] The evidence for each approach varies dramatically in depth and quality, and the distinction between FDA-approved therapies and experimental peptides is critical for understanding what is actually supported by clinical data. For specific details on each approach, see Growth Hormone Deficiency in Children: Peptide Treatment Options, Mecasermin (IGF-1): Treating Severe Growth Failure, and Sermorelin for Pediatric Growth: A GH-Releasing Alternative.
Key Takeaways
- Intranasal GHRP-2 at 5 to 15 micrograms per kilogram twice daily increased height velocity from 3.7 to 6.1 cm per year at 6 months in 15 children with short stature (Pihoker et al., Journal of Endocrinology, 1997)
- Sermorelin (GHRH analog) at 30 micrograms per kilogram per day increased height velocity from 4.1 to 8.0 cm per year at 6 months in growth hormone deficient children, though less than somatropin at equivalent doses
- Standard-dose recombinant GH (0.16 to 0.28 mg/kg/week) for idiopathic short stature produces a modest adult height gain of less than 4 cm on average, with individual responses highly variable
- Ipamorelin was identified as the first selective GH secretagogue in 1998, releasing GH without affecting cortisol or prolactin levels (Raun et al., European Journal of Endocrinology, 1998)
- Ghrelin, discovered in 1999 as the endogenous ligand for the GH secretagogue receptor, established the biological basis for GHRP action (Kojima et al., Nature, 1999)
- Macimorelin became the first oral GH secretagogue approved as a diagnostic tool for adult GH deficiency in 2017, demonstrating clinical translation of the GHRP concept (Garcia et al., Journal of Clinical Endocrinology and Metabolism, 2013)
The Growth Hormone Axis: Where Peptides Intervene
Growth in children depends on a cascade of peptide hormones. The hypothalamus releases GHRH, which stimulates the anterior pituitary to secrete growth hormone. GH then acts on the liver and other tissues to produce IGF-1, the peptide that directly drives bone and tissue growth. Somatostatin, another hypothalamic peptide, inhibits GH release, creating a pulsatile secretion pattern.
Each point in this axis represents a potential therapeutic target:
Hypothalamic level. GHRH analogs (sermorelin, tesamorelin) stimulate GH release by mimicking the natural releasing signal. GH secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin) act through the ghrelin receptor (GHS-R1a) to amplify GH pulses.
Pituitary level. Recombinant GH (somatropin) bypasses the entire upstream signaling pathway, delivering the hormone directly.
Peripheral level. Recombinant IGF-1 (mecasermin) bypasses both the hypothalamic-pituitary axis and GH, delivering the downstream growth factor directly to tissues.
The choice of intervention level matters clinically. Bowers documented in 1998 that growth hormone releasing peptides act synergistically with GHRH, meaning that combination approaches amplify GH release beyond what either peptide achieves alone.[3] This synergy between GHRPs and GHRH reflects the distinct receptor systems through which they operate.
Recombinant Growth Hormone: The Standard of Care
Somatropin (recombinant human GH) is the most extensively studied peptide therapy for short stature. It has been FDA-approved since 1985 for growth hormone deficiency (GHD) in children and subsequently for Turner syndrome, Prader-Willi syndrome, small for gestational age (SGA), chronic renal insufficiency, SHOX deficiency, Noonan syndrome, and idiopathic short stature (ISS).
Growth Hormone Deficiency
In children with confirmed GHD, somatropin replacement produces the most dramatic results. First-year height velocity typically increases from 4 to 5 cm per year to 10 to 12 cm per year. Johansson et al. documented in 1995 that GH replacement in GH-deficient adults improved body composition, reducing fat mass and increasing lean body mass, demonstrating that GH effects extend beyond linear growth.[5]
Idiopathic Short Stature
The ISS indication is more controversial. ISS describes children who are short (height below the 1.2nd percentile for age) without identifiable medical cause. Randomized controlled trials of somatropin for ISS show modest adult height gains. At standard doses of 0.16 to 0.28 mg per kilogram per week, the average gain over predicted adult height is less than 4 cm. Higher doses of 0.32 to 0.4 mg per kilogram per week have produced gains of 7 to 8 cm in some studies, but the number of trials at higher doses is limited.
The individual response to GH therapy in ISS is highly variable. No study has fulfilled evidence-based medicine criteria for both high quality of evidence and strong recommendation for GH use in ISS. The cost-benefit calculation for a therapy that requires years of daily injections and costs tens of thousands of dollars annually, in exchange for a few centimeters of additional height, remains contentious in pediatric endocrinology.
Growth Hormone Releasing Peptides: Stimulating Endogenous Production
GH releasing peptides represent a fundamentally different approach: instead of injecting GH directly, they stimulate the pituitary to release its own GH. This preserves the natural pulsatile pattern of GH secretion and, in theory, maintains physiological feedback regulation.
GHRP-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) that potently stimulates GH release. Pihoker et al.'s 1997 study is the most direct evidence for GHRP use in pediatric short stature. Fifteen children with height less than 2 standard deviations below mean for age received intranasal GHRP-2 at 5 to 15 micrograms per kilogram, twice daily for 3 months then three times daily. Height velocity increased from 3.7 plus or minus 0.2 cm per year to 6.1 plus or minus 0.3 cm per year at 6 months, sustained at 6.0 plus or minus 0.4 cm per year at 18 to 24 months.[1]
Half the children in this study were GH deficient and half had idiopathic short stature. Each child demonstrated a GH response above 10 micrograms per liter to intranasal GHRP-2, confirming pituitary responsiveness. The intranasal route was well tolerated with no significant adverse effects reported.
The growth velocity improvement of approximately 2.4 cm per year is meaningful but modest compared to somatropin replacement in GHD children. The advantage of GHRP-2 lies in its non-invasive administration (intranasal rather than subcutaneous injection) and preservation of physiological GH pulsatility.
GHRP-6 and Hexarelin
GHRP-6 was among the earliest GH secretagogues studied. It releases GH potently but also stimulates cortisol and prolactin secretion, limiting its selectivity as a growth-promoting agent. Berlanga-Acosta et al. reviewed the broader biological activities of GHRP-6 in 2024, documenting its cytoprotective and anti-inflammatory properties beyond GH release, suggesting the peptide has actions independent of the GH axis.[9]
Hexarelin showed the highest GH-releasing potency among early GHRPs. Brywe et al. demonstrated in 2005 that hexarelin reduced brain injury and improved functional outcome after hypoxia-ischemia in neonatal rats, an effect mediated through GH secretagogue receptors but independent of GH release itself.[12] This finding reveals that GH secretagogue receptors have neurological functions unrelated to growth, complicating the interpretation of what these peptides actually do in the body. For a deeper look at hexarelin, see Hexarelin: The Most Potent Growth Hormone Releasing Peptide.
Ipamorelin: Selectivity as a Design Goal
The problem with GHRP-2 and GHRP-6 was their lack of selectivity. They released GH but also stimulated ACTH, cortisol, and prolactin. Raun et al. identified ipamorelin in 1998 as the first truly selective GH secretagogue. At doses that produced robust GH release in rats and swine, ipamorelin did not affect plasma levels of ACTH, cortisol, prolactin, TSH, LH, or FSH.[6]
This selectivity made ipamorelin theoretically attractive for pediatric use, where unwanted hormonal effects during development are particularly concerning. However, ipamorelin has never been tested in clinical trials for pediatric short stature. It remains an investigational compound whose selectivity has been demonstrated in animals but not validated in growing children.
The Ghrelin Connection
The discovery of ghrelin by Kojima et al. in 1999 transformed understanding of GH secretagogue biology. Ghrelin, a 28-amino-acid peptide produced primarily in the stomach, was identified as the endogenous ligand for the GH secretagogue receptor (GHS-R1a).[4] This meant that synthetic GHRPs like GHRP-2 and GHRP-6 had been mimicking a natural stomach hormone all along.
Ghrelin's dual role as both a GH secretagogue and a hunger hormone connected growth regulation to nutritional status in a way that had not been previously appreciated. The GH secretagogue receptor is now understood to integrate nutritional signals with growth regulation, explaining why malnutrition impairs growth and why feeding status affects GH secretion patterns. Lu et al. reviewed the evolving understanding of GH secretagogue receptor signaling in 2024, documenting how the receptor functions as a metabolic sensor with implications far beyond GH release.[10]
GHRH Analogs: Sermorelin and Tesamorelin
Sermorelin
Sermorelin (GHRH 1-29) is the first 29 amino acids of the 44-amino-acid GHRH molecule, retaining full biological activity. It was FDA-approved in 1997 for diagnostic testing and treatment of children with GHD. In clinical trials, once-daily subcutaneous sermorelin at 30 micrograms per kilogram increased height velocity from 4.1 to 8.0 cm per year at 6 months in GH-deficient children. At 12 months, height velocity was 7.2 cm per year.
However, sermorelin produced lower growth responses than equivalent doses of somatropin in head-to-head comparisons. The manufacturer discontinued production in 2008 for commercial reasons, not safety concerns. Sermorelin requires an intact pituitary to work, meaning it cannot help children with pituitary destruction or congenital pituitary aplasia. For more on this peptide's history and mechanism, see Sermorelin for Pediatric Growth: A GH-Releasing Alternative and the broader context in Sermorelin: The Original Growth Hormone Releasing Peptide.
Tesamorelin
Tesamorelin is a modified GHRH analog (trans-3-hexenoic acid-GHRH 1-44) FDA-approved for lipodystrophy in HIV-infected adults, not for pediatric short stature. Makimura et al. evaluated tesamorelin's metabolic effects in 2014, documenting reduced visceral fat, improved lipid profiles, and increased IGF-1 levels in treated patients.[7] While tesamorelin has not been studied for growth promotion in children, its mechanism as a GHRH agonist means it could theoretically stimulate GH release in the same way as sermorelin. No pediatric growth trials exist.
Mecasermin (Recombinant IGF-1): Bypassing the GH Axis
Mecasermin (brand name Increlex) is recombinant human IGF-1 approved for children with severe primary IGF-1 deficiency. This includes children with GH gene deletions, GH receptor mutations (Laron syndrome), or post-GH receptor signaling defects who cannot respond to exogenous GH.
In these rare conditions, somatropin is ineffective because the problem lies downstream of GH signaling. Mecasermin delivers IGF-1 directly, bypassing the defective pathway. Clinical trials showed that mecasermin increased height velocity in children with severe primary IGFD, though the growth response was generally less than what GH achieves in GHD children.
Mecasermin carries distinct safety concerns: hypoglycemia is the most common adverse effect because IGF-1 has insulin-like metabolic actions. Tonsillar and adenoid hypertrophy, intracranial hypertension, and slipped capital femoral epiphysis have also been reported. The drug requires twice-daily subcutaneous injections administered with meals to mitigate hypoglycemia risk. For comprehensive coverage of this therapy, see Mecasermin (IGF-1): Treating Severe Growth Failure.
Oral GH Secretagogues: From Research Tool to Diagnostic
Ghigo et al. reviewed the prospect of orally active GH secretagogues in 1998, noting that several non-peptide compounds could stimulate GH release when taken by mouth.[8] This was a significant development because it opened the possibility of replacing daily injections with oral medications for growth promotion.
MK-677 (Ibutamoren)
MK-677 is a non-peptide GH secretagogue that mimics ghrelin action at the GHS-R1a receptor. It increases GH and IGF-1 levels when taken orally. However, MK-677 has never been FDA-approved for any indication and has not been tested in controlled trials for pediatric short stature. It is widely available through gray-market sources and marketed as a "growth hormone peptide," though it is technically not a peptide. For more context, see MK-677 (Ibutamoren): The Oral Growth Hormone Secretagogue.
Macimorelin
Macimorelin represents the most successful clinical translation of the GH secretagogue concept, though not for growth promotion. Garcia et al. demonstrated in 2013 that oral macimorelin-stimulated GH levels could reliably diagnose adult GH deficiency, establishing it as a diagnostic peptide rather than a therapeutic one.[11] The FDA approved macimorelin in 2017 as the first oral test for adult GH deficiency. Its success demonstrates that the GH secretagogue receptor can be targeted clinically, even though no GH secretagogue has been approved for growth promotion.
The Evidence Landscape: What Is Proven vs. What Is Marketed
The gap between proven and marketed peptide therapies for short stature is wide.
| Peptide | FDA Status for Growth | Evidence Level | Key Limitation |
|---|---|---|---|
| Somatropin (rhGH) | Approved (GHD, ISS, SGA, others) | Multiple RCTs | Daily injections, high cost, modest ISS benefit |
| Sermorelin | Formerly approved (discontinued 2008) | Phase III trials | Inferior to GH, requires intact pituitary |
| Mecasermin (rIGF-1) | Approved (severe primary IGFD only) | Phase III trials | Hypoglycemia risk, rare indication |
| GHRP-2 | Not approved | One 15-patient trial | No RCTs, limited long-term data |
| Ipamorelin | Not approved | Animal studies only | No human growth trials |
| MK-677 | Not approved | Adult studies only | No pediatric growth data |
| CJC-1295 | Not approved | Adult studies only | No pediatric growth data |
Argente et al. evaluated the clinical relevance of GH releasing peptides in 1996 and concluded that while they were valuable research tools for understanding GH physiology, their therapeutic role in pediatric growth remained to be established.[2] That assessment remains largely accurate three decades later. Bercu et al. similarly noted in 1997 that GH secretagogues held promise for both diagnostic and therapeutic applications in children, but that controlled clinical trials were needed to establish efficacy and safety for growth promotion.[13]
The broader picture of GH in disease states continues to evolve. Fakir et al. reviewed growth hormone's role across disease contexts in 2025, noting that GH and its related peptides affect metabolism, immunity, and tissue repair in ways that extend well beyond linear growth.[14] For how GH peptides influence sleep architecture, see How Growth Hormone Peptides Affect Sleep Quality: The Evidence. For the relationship between CJC-1295 and IGF-1 elevation, see CJC-1295 and IGF-1: What the Research Shows About Elevation.
Evidence Gaps and Open Questions
No head-to-head comparisons. GHRP-2 and ipamorelin have never been compared directly to somatropin in randomized controlled trials for pediatric growth. Without these comparisons, the relative efficacy of GH secretagogues versus GH replacement remains unknown.
Long-term safety in children. While somatropin has decades of post-marketing safety data in pediatric populations, GH secretagogues have minimal long-term safety data in children. The effects of chronic ghrelin receptor stimulation during development on appetite regulation, metabolic programming, and pubertal timing are unstudied.
Optimal timing and duration. The window during which peptide therapy can meaningfully influence adult height is bounded by growth plate closure. Whether starting GH or GH secretagogue therapy earlier produces proportionally better outcomes, and whether there is an age beyond which intervention is futile, are questions with incomplete answers.
Combination approaches. The synergy between GHRH and GHRPs documented by Bowers suggests that combination therapy could produce greater GH responses than either peptide alone.[3] No clinical trial has tested GHRH plus GHRP combination therapy in children with short stature.
Predictors of response. Individual response to GH therapy varies enormously. Identifying which children will respond well to which peptide approach, before committing to years of treatment, would transform clinical decision-making but remains an unsolved problem.
The Bottom Line
Peptide therapies for short stature span from the well-established (somatropin for GHD, mecasermin for severe primary IGF-1 deficiency) to the barely studied (ipamorelin, CJC-1295 for growth). The only GH secretagogue tested directly for pediatric growth velocity is GHRP-2, which produced a meaningful but modest increase in a single 15-patient trial. Sermorelin worked but was inferior to somatropin and was commercially discontinued. The evidence base narrows dramatically as you move from FDA-approved therapies to the peptides most commonly discussed in wellness and anti-aging contexts. For children with genuine growth hormone deficiency, somatropin remains the standard of care. For children without identifiable GH axis pathology, the evidence for any peptide intervention producing clinically significant adult height gains is limited.